Grochot, R., Han, H. S., Bellet, M., Hamilton, E. P., Sanchez-Bayona, R., Boni, V., LoRusso, P., Palmieri, C., Arkenau, H., Armstrong, A. C., Girgis, M., Vidula, N., Boomen, H. V. D., O'Shaughnessy, J. (2026). A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1151